Artificial Intelligence at the Helm: Revolutionizing the Life Sciences Sector (EY)
SaveSummary
- AI in the pharmaceuticals sector is expected to reach US$16.49 billion by 2034.p.8
- AI in the medical devices segment is projected to reach US$97.1 billion by 2028.p.8
- About 50% of CXOs in surveyed Indian life sciences organizations are already exploring GenAI actively, with budgets allocated or invested.p.12
- About 75% of CXOs in surveyed Indian life sciences organizations confirmed AI has been instrumental in reducing costs and driving customer satisfaction.p.12
- GenAI advancements in healthcare are driving about 13% improvement in labor efficiency.p.12
- India invested approximately INR 10,300 crore in March 2024 in the IndiaAI Mission.p.18
Key insights
- AI in pharmaceuticals is expected to reach US$16.49 billion by 2034, driven by drug discovery, clinical trials and personalized healthcare.p.8
- AI in medical devices is projected to reach US$97.1 billion by 2028 on diagnostic tools, smart devices, wearables and surgical robotics.p.8
- Challenges to AI adoption fall into ethical, technical and operational categories.p.9
- AI maturity is categorized into three levels: foundational, innovative and transformational.p.9
- As of 2023, AlphaFold has predicted over 200 million protein structures.p.15
- The EU AI Act is among the regulations governing AI in life sciences in Europe, alongside GDPR.p.16
- India committed approximately INR 10,300 crore in March 2024 to the IndiaAI Mission.p.18
Topics and entities
Summary and figures generated from the document and checked automatically: every number shown appears on the cited page. The full document is available from the publisher. Publishers can request removal.